Current Utility of Chimeric Antigen Receptor T-Cell Therapy in Non-Small Cell Lung Cancer

this study paved Abstract Although the utilization of chimeric antigen receptor (CAR) T-cells for the treatment of non-small cell lung cancer (NSCLC) has traditionally been severely limited, numerous recent technological advancements have allowed for rapid progression of the field in various forms. With the maturation of techniques such as genotyping, immunohistochemistry, large-scale antibody production, and ultra-high throughput screening among many others, the production of novel NSCLC-focused CAR T-cells encompassing a wide array of structural designs and functions has yet to undergo a transition comparable to that of the previous decade. Indeed, the number and quality of modern antigens, antibodies, short-chain variable fragment (scFv) sequences, ligands, and inhibitors available for designing and bioengineering CARs have allowed for a markedly increased understanding of the mechanisms and processes necessary for the successful production of a CAR T-cell line. Most notably, advances in antigen understanding, targeting, and manipulation, CAR module integration, interaction, and compatibility, and immune cell modulation are three approaches currently at the focal point of NSCLC-focused CAR T-cell production. Herein, we briefly discuss the current status of each of these three strategies; novel targeting of NSCLC tumor-specific antigens, bispecific and physiological CAR T-cells, and inhibitory CAR T-cells, in the ongoing development of viable NSCLC management options.